Venezuelan Currency Devaluation: 4 Companies to Watch: The Procter & Gamble Company (PG) and More

Page 1 of 2

Is it within the realm of possibility that Hugo Chavez is just a bit of a control freak? On Friday of last week, the colorful Venezuelan leader, currently undergoing treatment for cancer in Cuba, once again asserted his formidable command over the Venezuelan economy by remotely ordering a 32% devaluation of his country’s currency, the bolivar, against the U.S. dollar. This latest front in Chavez’s mercurial economic policy is partly intended to finance massive government debt spending incurred in the run-up to his reelection last year. It’s particularly vexing for multinationals that perennially attempt to crack the Venezuelan consumer market, despite the risks. Let’s take a look at the impact of the bolivar devaluation on four popular consumer-based companies with Venezuelan exposure:

The Procter & Gamble Company (NYSE:PG)

Colgate-Palmolive Company (NYSE:CL)
Colgate’s sales and earnings were already facing pressure from Venezuela in late 2012. Economic uncertainty coupled with a labor slowdown in the company’s local Venezuelan production facility shaved a full 1.5% off Colgate’s worldwide organic sales and 50 basis points off its worldwide gross margin in the fourth quarter. When pressed by analysts during its fourth-quarter 2012 earnings call on Jan. 31, CEO Ian Cook declined to quantify the impact of a then-potential bolivar devaluation. The company had projected double-digit earnings-per-share growth in 2013, and Cook was careful to stress that “the double digit in dollar terms of guidance was absent a macroeconomic devaluation in Venezuela.”Cook also stated that if devaluation occurred, Colgate would issue related guidance “swiftly.”

True to Cook’s word, on Monday of this week following the devaluation, Colgate issued a press release stating that the company would take balance-sheet-related charges of $0.25 per share in the first quarter on its Venezuelan domiciled assets, as well as between $0.05 to $0.07 in per-share earnings reductions for each quarter of 2013. All told, these charges equal roughly $0.50 per share. Taking into account Colgate’s $5.15 earnings per share in 2012, this single event may have just wiped out the company’s goal of double-digit 2013 EPS growth.

The Clorox Company (NYSE:CLX)
Give Clorox a gold star for dealing proactively with the prospect of a bolivar slide. On releasing second-quarter 2013 earnings on Feb. 4, Clorox had already factored in a range of $0.05 to $0.10 earnings impact in its forward guidance due to what it deemed a likely bolivar devaluation. Venezuela accounts for roughly 2% of Clorox’s sales, and the devaluation effects may hit the top of the projected impact range or slightly exceed it. Of course, Clorox and all companies operating in Venezuela have some exposure to potential further devaluation this year. Frontier Strategy Group, a consultancy that predicted the currency’s weakening to the exact percentage point of 32% four months ago, expects that the devaluation could continue this year to a total of 55% to 60%. All in all, though, shareholders should be pleased that Clorox is actively forecasting and absorbing the earnings impacts in real time. This will make it easier to evaluate the rest of Clorox’s global earnings each quarter in 2013.

The Procter & Gamble Company (NYSE:PG)
Similar to Colgate and Clorox, P&G held a recent earnings call before the Feb. 8 devaluation, on Jan. 25, when it released its second-quarter 2013 earnings. However, where its peers clearly saw the bolivar’s devaluation as a probable event, and discussed it at length on their earnings calls, P&G treated devaluation as more of a possibility; one among several documented business risks. In its quarterly SEC filing, besides an obligatory currency disclosure denoting Venezuela as a high-inflation economy, the company mentioned devaluation risk almost as if in passing. On the Jan. 25 earnings call, it was similarly only mentioned once.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!